SLC22A15 inhibitors are a class of chemical compounds designed to specifically block the activity of the solute carrier family 22 member 15 (SLC22A15) protein, which is a part of the larger SLC22 family of transporters. This family is known for transporting organic cations, anions, and zwitterions across cellular membranes. SLC22A15, in particular, is thought to facilitate the movement of certain organic molecules, potentially including amino acids, metabolites, or other substrates essential for cellular metabolism and homeostasis. Inhibitors of SLC22A15 act by binding to critical regions of the transporter, interfering with its ability to recognize or translocate these substrates across the cell membrane. This inhibition disrupts the normal flux of organic molecules, affecting various biochemical pathways that depend on the transport of these substrates for proper cellular function.
The design and development of SLC22A15 inhibitors rely on detailed knowledge of the transporter's structure and the mechanism of substrate transport. Researchers utilize molecular modeling, computational simulations, and structural techniques such as X-ray crystallography to identify the binding sites and structural conformations essential for SLC22A15 activity. Inhibitors are then crafted to selectively bind to these sites, blocking the transporter without impacting other related proteins in the SLC family. These inhibitors are evaluated using biochemical assays and transport studies to determine their effectiveness, binding affinity, and specificity. By inhibiting SLC22A15, researchers can study the role of this transporter in cellular and systemic metabolism, exploring how it contributes to processes such as nutrient absorption, waste elimination, and the regulation of small molecule homeostasis. The study of these inhibitors advances the understanding of how organic cation transporters like SLC22A15 function within the broader network of cellular transport systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine, a histamine H2 receptor antagonist, has been shown to inhibit various organic cation transporters (OCTs) by competing for transport, potentially affecting SLC22A15 activity indirectly. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine, a class I antiarrhythmic agent, is known to inhibit several OCTs by blocking the transport of organic cations, which might also extend to SLC22A15. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can inhibit OCTs by altering cellular ionic balance, possibly influencing SLC22A15 function. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $67.00 $161.00 $255.00 $721.00 $3401.00 | 4 | |
Trimethoprim, an antibiotic, has been reported to inhibit organic cation transport, potentially affecting SLC22A15 by interfering with its substrate specificity or transport efficiency. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Probenecid is known to inhibit various transporters involved in renal clearance, which may indirectly affect SLC22A15's function in organic cation transport. | ||||||
Ranitidine | 66357-35-5 | sc-203679 | 1 g | $193.00 | ||
Ranitidine, another H2 receptor antagonist, can inhibit OCTs, suggesting potential indirect effects on SLC22A15 activity by altering substrate availability. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole inhibits multiple drug transporters, which could include effects on OCT family members, potentially influencing SLC22A15. | ||||||
1-Adamantylamine | 768-94-5 | sc-251475 sc-251475A | 1 g 25 g | $39.00 $147.00 | ||
Amantadine, an antiviral and antiparkinsonian drug, has been shown to interact with OCTs, possibly affecting SLC22A15 activity by competing for transport. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine, an immunosuppressant, inhibits several drug transporters and could indirectly affect SLC22A15 function through modulating cellular transport processes. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem, a calcium channel blocker like verapamil, may influence OCT activity and thereby indirectly affect SLC22A15's role in organic cation transport. | ||||||